EP Patent

EP2656841A1 — Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases

Assigned to University of California · Expires 2013-10-30 · 13y expired

What this patent protects

A hydantoin compound according to formula II: wherein R 2 and R 3 together with the carbon to which they are linked form a cycle, or a pharmaceutically acceptable salt thereof, useful for the prevention or treatment of hyperproliferative diseases or disorders.

USPTO Abstract

A hydantoin compound according to formula II: wherein R 2 and R 3 together with the carbon to which they are linked form a cycle, or a pharmaceutically acceptable salt thereof, useful for the prevention or treatment of hyperproliferative diseases or disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP2656841A1
Jurisdiction
EP
Classification
—
Expires
2013-10-30
Drug substance claim
No
Drug product claim
No
Assignee
University of California
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.